FDA approval
| 7 min read
They’re approved by the FDA and Medicare and inching closer to widespread adoption nationally. But how good are they at detecting colorectal cancer?
| 4 min read
Another biotech retreats from AAV, a promising antibiotic, a paused CRISPR trial, and more led the news this week.
| 3 min read
Papzimeos is the first FDA-approved therapy for recurrent respiratory papillomatosis, a rare HPV-driven disease that has long forced patients into repeated surgeries.
| 4 min read
The HDAC inhibitor givinostat has received regulatory approval in the US, EU, and UK for patients six years and older.
| 3 min read
Promising new therapies for Huntington’s disease and multiple myeloma, the first FDA approval for Barth syndrome, and more led the news this week.
| 3 min read
The new diagnostic enables rapid identification of acute leukaemia patients with KMT2A rearrangements for precision therapy.
| 2 min read
A disease once synonymous with a shortened lifespan is now a model for how drug discovery can directly alter the natural history of genetic disorders.
| 3 min read
Blood tests can’t diagnose Alzheimer’s disease yet, but one is already approved and more are on the way.
| 4 min read
Long-term treatment with givinostat can significantly delay loss of key mobility functions in patients with DMD
| 2 min read
Qfitlia, an RNAi therapeutic given every two months, is the first to target the antithrombin protein instead of missing clotting factors in the blood.
